Richard I Fisher

Summary

Affiliation: University of Rochester
Country: USA

Publications

  1. ncbi Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas
    Richard I Fisher
    University of Rochester School of Medicine, James P Wilmot Cancer Center, 601 Elmwood Ave, Box 704, Rochester, NY 14642, USA
    J Clin Oncol 23:7565-73. 2005
  2. ncbi New treatment options have changed the survival of patients with follicular lymphoma
    Richard I Fisher
    James P Wilmot Cancer Center, University of Rochester, Rochester, NY, USA
    J Clin Oncol 23:8447-52. 2005
  3. ncbi Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma
    Richard I Fisher
    University of Rochester, James P Wilmot Cancer Center, Rochester, USA
    J Clin Oncol 24:4867-74. 2006
  4. doi Involved field radiation after autologous stem cell transplant for diffuse large B-cell lymphoma in the rituximab era
    Tithi Biswas
    Department of Radiation Oncology, University of Rochester Medical Center, Rochester, New York 14642, USA
    Int J Radiat Oncol Biol Phys 77:79-85. 2010
  5. ncbi Advances in the treatment of hematologic malignancies. Part 1 of a 3-part series: Aggressive lymphomas
    Richard I Fisher
    James P Wilmot Cancer Center, University of Rochester, NY, USA
    Clin Adv Hematol Oncol 4:suppl 1, 4-9; discussion suppl 10; quiz 2 p following suppl 10. 2006
  6. pmc Late relapses following high-dose autologous stem cell transplantation (HD-ASCT) for Hodgkin's lymphoma (HL) in the ABVD therapeutic era
    Sarah F Keller
    James P Wilmot Cancer Center, University of Rochester, Rochester, New York 14642, USA
    Biol Blood Marrow Transplant 18:640-7. 2012
  7. pmc The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma
    Jonathan W Friedberg
    James P Wilmot Cancer Center, University of Rochester, Rochester, NYm, USA
    Blood 117:2807-12. 2011
  8. ncbi Novel concepts in radioimmunotherapy for non-Hodgkin's lymphoma
    Julia Schaefer-Cutillo
    James P Wilmot Cancer Center, University of Rochester Medical Center, Rochester, New York 14642, USA
    Oncology (Williston Park) 21:203-12; discussion 214, 217, 221. 2007
  9. ncbi Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma
    Thomas M Habermann
    Division of Hematology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    J Clin Oncol 24:3121-7. 2006
  10. doi Natural history of CNS relapse in patients with aggressive non-Hodgkin's lymphoma: a 20-year follow-up analysis of SWOG 8516 -- the Southwest Oncology Group
    Steven H Bernstein
    James P Wilmot Cancer Center, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, USA
    J Clin Oncol 27:114-9. 2009

Detail Information

Publications59

  1. ncbi Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas
    Richard I Fisher
    University of Rochester School of Medicine, James P Wilmot Cancer Center, 601 Elmwood Ave, Box 704, Rochester, NY 14642, USA
    J Clin Oncol 23:7565-73. 2005
    ....
  2. ncbi New treatment options have changed the survival of patients with follicular lymphoma
    Richard I Fisher
    James P Wilmot Cancer Center, University of Rochester, Rochester, NY, USA
    J Clin Oncol 23:8447-52. 2005
    ..However, multiple new treatment options have been developed in the last decade, and their impact on survival of follicular lymphoma remains unknown...
  3. ncbi Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma
    Richard I Fisher
    University of Rochester, James P Wilmot Cancer Center, Rochester, USA
    J Clin Oncol 24:4867-74. 2006
    ..Evaluate response rate, duration of response (DOR), time-to-progression (TTP), overall survival (OS), and safety of bortezomib treatment in patients with relapsed or refractory mantle cell lymphoma (MCL)...
  4. doi Involved field radiation after autologous stem cell transplant for diffuse large B-cell lymphoma in the rituximab era
    Tithi Biswas
    Department of Radiation Oncology, University of Rochester Medical Center, Rochester, New York 14642, USA
    Int J Radiat Oncol Biol Phys 77:79-85. 2010
    ..We evaluated the role of involved field radiation therapy (IFRT) post-ASCT for patients initially induced with cyclophosphamide, adriamycin, vincristine, and prednisone (CHOP) or, more recently, rituximab-CHOP (R-CHOP)...
  5. ncbi Advances in the treatment of hematologic malignancies. Part 1 of a 3-part series: Aggressive lymphomas
    Richard I Fisher
    James P Wilmot Cancer Center, University of Rochester, NY, USA
    Clin Adv Hematol Oncol 4:suppl 1, 4-9; discussion suppl 10; quiz 2 p following suppl 10. 2006
    ..Recent and ongoing studies are moving us closer towards that goal...
  6. pmc Late relapses following high-dose autologous stem cell transplantation (HD-ASCT) for Hodgkin's lymphoma (HL) in the ABVD therapeutic era
    Sarah F Keller
    James P Wilmot Cancer Center, University of Rochester, Rochester, New York 14642, USA
    Biol Blood Marrow Transplant 18:640-7. 2012
    ..Our results emphasize the importance of long-term follow-up for both toxicity and recurrence, and have important implications in defining success of posttransplantation maintenance strategies...
  7. pmc The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma
    Jonathan W Friedberg
    James P Wilmot Cancer Center, University of Rochester, Rochester, NYm, USA
    Blood 117:2807-12. 2011
    ..On the basis of these promising results, the US cooperative groups have initiated randomized trials to evaluate this regimen in follicular and mantle cell lymphoma. This trial was registered at www.clinicaltrials.gov as #NCT00547534...
  8. ncbi Novel concepts in radioimmunotherapy for non-Hodgkin's lymphoma
    Julia Schaefer-Cutillo
    James P Wilmot Cancer Center, University of Rochester Medical Center, Rochester, New York 14642, USA
    Oncology (Williston Park) 21:203-12; discussion 214, 217, 221. 2007
    ....
  9. ncbi Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma
    Thomas M Habermann
    Division of Hematology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    J Clin Oncol 24:3121-7. 2006
    ....
  10. doi Natural history of CNS relapse in patients with aggressive non-Hodgkin's lymphoma: a 20-year follow-up analysis of SWOG 8516 -- the Southwest Oncology Group
    Steven H Bernstein
    James P Wilmot Cancer Center, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, USA
    J Clin Oncol 27:114-9. 2009
    ..To investigate the incidence, natural history, and risk factors predictive of CNS relapse in patients with de novo aggressive lymphomas and to evaluate the efficacy of CNS prophylaxis in patients with initial bone marrow (BM) involvement...
  11. ncbi Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study
    Gary H Lyman
    James P Wilmot Cancer Center, University of Rochester Medical Center, 601 Elmwood Ave, Rochester, NY 14642, USA
    J Clin Oncol 22:4302-11. 2004
    ..To assess the incidence of and risk factors for reduced relative dose-intensity (RDI) in patients treated with chemotherapy for aggressive non-Hodgkin's lymphoma (NHL)...
  12. pmc Phase II study of a TLR-9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphoma
    Jonathan W Friedberg
    James P Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY, USA
    Br J Haematol 146:282-91. 2009
    ..This study is the first to histologically confirm perturbation of the local immune microenvironment following systemic biological therapy of follicular lymphoma...
  13. pmc Rituximab immunotherapy results in the induction of a lymphoma idiotype-specific T-cell response in patients with follicular lymphoma: support for a "vaccinal effect" of rituximab
    Shannon P Hilchey
    James P Wilmot Cancer Center, Aab Institute of Biomedical Sciences, and Department of Microbiology and Immunology, School of Medicine and Dentistry, University of Rochester, NY 14642, USA
    Blood 113:3809-12. 2009
    ..Our data thus provide "proof of principle" for the ability of passive immunotherapy with rituximab to elicit an active FL-specific cellular response...
  14. doi Profound hypogammaglobulinemia 7 years after treatment for indolent lymphoma
    Alison R Walker
    University of Rochester, Hematology Oncology, Rochester, New York 14642, USA alison
    Cancer Invest 26:431-3. 2008
    ..The patient was started on monthly intravenous immunoglobulin treatments with complete resolution of her symptoms...
  15. ncbi Iodine-131 tositumomab (Bexxar): radioimmunoconjugate therapy for indolent and transformed B-cell non-Hodgkin's lymphoma
    Jonathan W Friedberg
    Lymphoma Program, James P Wilmot Cancer Center, University of Rochester, Rochester, NY 14642, USA
    Expert Rev Anticancer Ther 4:18-26. 2004
    ..Studies are also addressing the role of iodine-131 tositumomab as a component of initial therapy for indolent non-Hodgkin's lymphoma and in additional histologies of non-Hodgkin's lymphoma...
  16. pmc Diffuse large B-cell lymphoma
    Jonathan W Friedberg
    James P Wilmot Cancer Center, University of Rochester, 601 Elmwood Avenue, Box 704, Room 1 4118C, Rochester, NY 14642, USA
    Hematol Oncol Clin North Am 22:941-52, ix. 2008
    ....
  17. doi Evaluation of the International Prognostic Score (IPS-7) and a Simpler Prognostic Score (IPS-3) for advanced Hodgkin lymphoma in the modern era
    Catherine S Diefenbach
    New York University, New York, NY, USA
    Br J Haematol 171:530-8. 2015
    ..For patients with advanced HL, the IPS-3 may provide a simpler and more accurate framework for risk assessment in the modern era. Validation of these findings in other large data sets is planned. ..
  18. ncbi B cell reconstitution after rituximab treatment of lymphoma recapitulates B cell ontogeny
    Jennifer H Anolik
    Department of Medicine, Division of Clinical Immunology and Rheumatology, James P Wilmot Cancer Center, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, USA
    Clin Immunol 122:139-45. 2007
    ..0001). Expansion of functionally immature B cells and decreased memory B cells may contribute to an immunodeficient state in patients recovering from rituximab mediated B cell depletion, particularly with repeated treatment...
  19. pmc R-CHOP with iodine-131 tositumomab consolidation for advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0433
    Jonathan W Friedberg
    James P Wilmot Cancer Center, University of Rochester, Rochester, NY, USA
    Br J Haematol 166:382-9. 2014
    ....
  20. ncbi Thromboembolism in hospitalized neutropenic cancer patients
    Alok A Khorana
    James P Wilmot Cancer Center and the Department of Medicine, University of Rochester, Rochester, NY, USA
    J Clin Oncol 24:484-90. 2006
    ..We investigated venous and arterial thromboembolism and associated outcomes in hospitalized cancer patients actively receiving therapy, as identified by neutropenia...
  21. ncbi The epidemiology of non-Hodgkin's lymphoma
    Susan G Fisher
    Division of Epidemiology, Department of Community and Preventive Medicine, University of Rochester School of Medicine and Dentistry, 601 Elmwood Avenue, Box 644, New York 14642, USA
    Oncogene 23:6524-34. 2004
    ..We must build on our current knowledge regarding the etiology of NHL in order that prevention, treatment, and ultimately, cure of this malignancy becomes a reality...
  22. pmc Low Serum Vitamin D Levels Are Associated With Inferior Survival in Follicular Lymphoma: A Prospective Evaluation in SWOG and LYSA Studies
    Jennifer L Kelly
    Jennifer L Kelly and Jonathan W Friedberg, James P Wilmot Cancer Center, University of Rochester School of Medicine and Dentistry, Rochester, NY Gilles Salles, Hospices Civils de Lyon, Universite Claude Bernard Lyon 1, Pierre Benite Pauline Brice, Assistance Publique Hopitaux de Paris, Hopital Saint Louis, Paris Olivier Casasnovas, Centre hospitalo universitaire de Dijon, Dijon Pierre Soubeyran, Institut Bergonié and Université Victor Segalen Bordeaux 2, Bordeaux Corinne Haioun, Assistance Publique Hopitaux de Paris, Hopital Henri Mondor, Créteil Luc Xerri, Institut Paoli Calmettes, Marseille Hervé Tilly, Centre Henri Becquerel, Rouen, France Bryan Goldman, Oliver Press, and Michael LeBlanc, SWOG Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, WA Richard I Fisher, Fox Chase Cancer Center, Temple University School of Medicine, Philadelphia, PA and Lisa Rimsza, University of Arizona, Tucson, AZ
    J Clin Oncol 33:1482-90. 2015
    ..Recent literature reports a potential association between high vitamin D and improved lymphoma prognosis. We evaluated the impact of pretreatment vitamin D on follicular lymphoma (FL) outcome...
  23. pmc Phase 2 study of imexon, a prooxidant molecule, in relapsed and refractory B-cell non-Hodgkin lymphoma
    Paul M Barr
    University of Rochester, Wilmot Cancer Center, Rochester, NY
    Blood 124:1259-65. 2014
    ..Therefore, pretreatment markers of oxidative stress may identify patients likely to respond to this therapeutic approach. This trial was registered at www.clinicaltrials.gov as #NCT01314014. ..
  24. ncbi Overview of non-Hodgkin's lymphoma: biology, staging, and treatment
    Richard I Fisher
    James P Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY 14642, USA
    Semin Oncol 30:3-9. 2003
    ..Recent data suggest that high-dose therapy with stem cell support may be the treatment of choice for patients with relapsed aggressive lymphomas that remain chemosensitive...
  25. pmc Outcomes of patients with Burkitt lymphoma older than age 40 treated with intensive chemotherapeutic regimens
    Jennifer L Kelly
    James P Wilmot Cancer Center, University of Rochester, Rochester, NY 14642, USA
    Clin Lymphoma Myeloma 9:307-10. 2009
    ....
  26. ncbi Treatment of diffuse large B-cell lymphomas
    Richard I Fisher
    University of Rochester Medical Center, Rochester, NY, USA
    Semin Hematol 43:205-6. 2006
  27. ncbi Diffuse large B-cell NHL
    Jonathan W Friedberg
    University of Rochester Medical Center, James P Wilmot Cancer Center, Lymphoma Program 601 Elmwood Avenue, Box 704 Rochester, NY 14642, USA
    Cancer Treat Res 131:121-40. 2006
  28. pmc Randomized Phase III Trial Comparing ABVD Plus Radiotherapy With the Stanford V Regimen in Patients With Stages I or II Locally Extensive, Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the North American Intergroup E2496 Trial
    Ranjana H Advani
    Ranjana H Advani, Richard T Hoppe, and Sandra J Horning, Stanford University, Stanford Joseph M Tuscano, University of California, Davis Cancer Center, Sacramento, CA Fangxin Hong, Dana Farber Cancer Institute, Boston, MA Richard I Fisher and Jonathan W Friedberg, University of Rochester, Rochester, NY Nancy L Bartlett, Washington University School of Medicine, St Louis, MO K Sue Robinson, Queen Elizabeth II Health Science Center, Halifax, Nova Scotia Randy D Gascoyne, British Columbia Cancer Agency, Vancouver, British Columbia Douglas A Stewart, Tim Baker Cancer Institute, Calgary, Alberta, Canada Henry Wagner Jr, Penn State Cancer Institute, Hershey, PA Patrick J Stiff, Loyola University Medical Center, Maywood Leo I Gordon, Northwestern University, Chicago, IL Bruce D Cheson, Georgetown University Hospital, Washington, DC Brad S Kahl, University of Wisconsin, Madison, WI Kristie A Blum, Ohio State University, Columbus
    J Clin Oncol 33:1936-42. 2015
    ..We report results of a planned subgroup analysis in patients with stage I or II bulky mediastinal Hodgkin lymphoma (HL)...
  29. ncbi The emerging concept of antigen-driven lymphomas: epidemiology and treatment implications
    Susan G Fisher
    Division of Epidemiology, Department of Community and Preventive Medicine and James P Wilmot Cancer Center, University of Rochester, Rochester, New York 14642, USA
    Curr Opin Oncol 18:417-24. 2006
    ..This review discusses the current evidence for the role of foreign or self antigens in the initiation of lymphomagenesis...
  30. ncbi The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of diffuse large cell B-cell non-Hodgkin's lymphoma
    Theresa Hahn
    Roswell Park Cancer Institute, Buffalo, NY, USA
    Biol Blood Marrow Transplant 9:667. 2003
  31. ncbi The value of augmented preparative regimens combined with an autologous bone marrow transplant for the management of relapsed or refractory Hodgkin disease: a Southwest Oncology Group phase II trial
    Patrick J Stiff
    Loyola University Stritch School of Medicine, Maywood, Illinois, USA
    Biol Blood Marrow Transplant 9:529-39. 2003
    ..A poor-prognosis group was identified that should be treated with novel therapies...
  32. ncbi Combination of fludarabine and mitoxantrone in untreated stages III and IV low-grade lymphoma: S9501
    William S Velasquez
    University of Texas Medical Branch, Galveston, USA
    J Clin Oncol 21:1996-2003. 2003
    ..To determine the efficacy of combination fludarabine and mitoxantrone (FN) in untreated stages III and IV low-grade lymphoma. The major end point was to estimate progression-free survival (PFS) in all eligible patients...
  33. ncbi A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911
    Oliver W Press
    Fred Hutchinson Cancer Research Center, D3 190, 1100 Fairview Ave, Seattle, WA 98109, USA
    Blood 102:1606-12. 2003
    ..This novel treatment appears promising compared with the SWOG's historical experience using CHOP alone and is currently being compared with CHOP plus rituximab in a randomized phase 3 trial (S0016)...
  34. ncbi Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells
    Sandeep S Dave
    National Cancer Institute, NIH, Bethesda, MD 20892, USA
    N Engl J Med 351:2159-69. 2004
    ..We used gene-expression profiles of tumor-biopsy specimens obtained at diagnosis to develop a molecular predictor of the length of survival...
  35. ncbi Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial
    David B Duggan
    Department of Medicine, State University of New York Upstate Medical University, 750 East Adams Street, Syracuse, NY 13210, USA
    J Clin Oncol 21:607-14. 2003
    ..We compared these regimens as initial chemotherapy for Hodgkin's disease...
  36. ncbi The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma
    Andreas Rosenwald
    Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    N Engl J Med 346:1937-47. 2002
    ..The survival of patients with diffuse large-B-cell lymphoma after chemotherapy is influenced by molecular features of the tumors. We used the gene-expression profiles of these lymphomas to develop a molecular predictor of survival...
  37. ncbi Dose-intense chemotherapy every 2 weeks with dose-intense cyclophosphamide, doxorubicin, vincristine, and prednisone may improve survival in intermediate- and high-grade lymphoma: a phase II study of the Southwest Oncology Group (SWOG 9349)
    Douglas W Blayney
    Wilshire Oncology Medical Group, Inc, Pasadena, CA, USA
    J Clin Oncol 21:2466-73. 2003
    ....
  38. ncbi Autologous stem-cell transplantation as a component of initial treatment for poor-risk patients with aggressive non-Hodgkin's lymphoma: resolved issues versus remaining opportunity
    Richard I Fisher
    J Clin Oncol 20:4411-2. 2002
  39. doi Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014
    Daniel O Persky
    Arizona Cancer Center, University of Arizona, Tucson, AZ, USA
    J Clin Oncol 26:2258-63. 2008
    ....
  40. ncbi Overview of Southwest Oncology Group clinical trials in non-Hodgkin lymphoma
    Richard I Fisher
    Clin Adv Hematol Oncol 3:544-6. 2005
  41. pmc Total body irradiation, etoposide, cyclophosphamide, and autologous peripheral blood stem-cell transplantation followed by randomization to therapy with interleukin-2 versus observation for patients with non-Hodgkin lymphoma: results of a phase 3 randomiz
    John A Thompson
    Puget Sound Oncology Consortium, Seattle, WA, USA
    Blood 111:4048-54. 2008
    ..Posttransplantation IL-2 given at this dose and schedule of administration had no significant effect on PFS or OS. This study is registered at www.clinicaltrials.gov as NCT00002649...
  42. ncbi Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911
    Oliver W Press
    Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    J Clin Oncol 24:4143-9. 2006
    ..This study was performed to determine the efficacy of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy followed by tositumomab/iodine I-131 tositumomab...
  43. pmc Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study
    Jane N Winter
    Robert H Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA
    Blood 107:4207-13. 2006
    ..Our finding that Bcl-6(+) cases did not benefit from the addition of R to CHOP requires independent confirmation...
  44. ncbi Mantle cell lymphoma: at last, some hope for successful innovative treatment strategies
    Richard I Fisher
    J Clin Oncol 23:657-8. 2005
  45. ncbi Overview of Southwest Oncology Group Clinical Trials in non-Hodgkin Lymphoma. S0016. A phase III trial of CHOP vs CHOP + rituximab vs CHOP + iodine131-labeled monoclonal anti-B1 antibody (tositumomab) for treatment of newly diagnosed follicular NHL
    Richard I Fisher
    Clin Adv Hematol Oncol 3:544-6. 2005
  46. ncbi Alteration of SMRT tumor suppressor function in transformed non-Hodgkin lymphomas
    Lynda Song
    Department of Medicine, Cardinal Bernardin Cancer Center, Loyola University Medical Center, Maywood, Illinois, USA
    Cancer Res 65:4554-61. 2005
    ..Assessment of cDNA array profiles should further help us to design a working model for SMRT involvement in non-Hodgkin lymphoma transformation as a novel, nonclassical tumor suppressor...
  47. pmc Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction
    Silvia Bea
    Department of Pathology and Hematology Hospital Clinic, University of Barcelona, Spain
    Blood 106:3183-90. 2005
    ..In addition, gains involving the chromosomal region 3p11-p12 provided prognostic information that was statistically independent of the previously defined gene-expression-based survival model, thereby improving its predictive power...
  48. ncbi Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular
    Lisa M Rimsza
    Department of Pathology, College of Medicine, University of Arizona, 1501 N Campbell Ave, PO Box 245043, Tucson, AZ 85724 5043, USA
    Blood 103:4251-8. 2004
    ..8% versus 11.0%; P =.001), supporting the hypothesis that loss of tumor immunosurveillance has a devastating effect on patient outcome in DLBCL...
  49. ncbi Molecular diagnosis of Burkitt's lymphoma
    Sandeep S Dave
    National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    N Engl J Med 354:2431-42. 2006
    ..We examined whether gene-expression profiling could reliably distinguish Burkitt's lymphoma from diffuse large-B-cell lymphoma...
  50. ncbi Venous thromboembolism in patients with diffuse large B-cell lymphoma
    Rami S Komrokji
    Department of Medicine, University of Cincinnati and Cincinnati Veterans Administration Medical Center, Cincinnati, OH 45267 0501, USA
    Leuk Lymphoma 47:1029-33. 2006
    ..2 years (95% CI 1.8 - 8.6) for those without VTE (P = 0.038). We conclude that VTE is a frequent complication of DLBCL that occurs particularly at diagnosis and during initial therapy, and it is associated with a worse prognosis...
  51. ncbi Health status and quality of life in patients with early-stage Hodgkin's disease treated on Southwest Oncology Group Study 9133
    Patricia A Ganz
    University of California, Los Angeles, Los Angeles, CA, USA
    J Clin Oncol 21:3512-9. 2003
    ....
  52. ncbi The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma
    Andreas Rosenwald
    The Lymphoma Leukemia Molecular Profiling Project, National Cancer Institute NIH, Bethesda, MD, USA
    Cancer Cell 3:185-97. 2003
    ..We propose a quantitative model of the aberrant cell cycle regulation in MCL that provides a rationale for the design of cell cycle inhibitor therapy in this malignancy...
  53. pmc Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma
    Andreas Rosenwald
    Metabolism Branch, National Cancer Institute, National Institute of Health, Bethesda, MD 20892, USA
    J Exp Med 198:851-62. 2003
    ..The molecular diagnosis of PMBL should significantly aid in the development of therapies tailored to this clinically and pathogenetically distinctive subgroup of DLBCL...
  54. ncbi Follicular lymphoma international prognostic index
    Philippe Solal-Celigny
    Centre Jean Bernard, 9 rue Beauverger, 72000 Le Mans, France
    Blood 104:1258-65. 2004
    ..Results were very similar in the confirmation group. The FLIPI may be used for improving treatment choices, comparing clinical trials, and designing studies to evaluate new treatments...
  55. pmc Prospective study of sequential reduction in immunosuppression, interferon alpha-2B, and chemotherapy for posttransplantation lymphoproliferative disorder
    Lode J Swinnen
    Department of Oncology, Johns Hopkins School of Medicine, Cancer Research Building 2M89, Baltimore, MD 21231, USA
    Transplantation 86:215-22. 2008
    ..The design predated rituximab...
  56. pmc Point mutations and genomic deletions in CCND1 create stable truncated cyclin D1 mRNAs that are associated with increased proliferation rate and shorter survival
    Adrian Wiestner
    Center for Cancer Research, National Cancer Institute, National Institutes of Health, 9000 Rockville Pike, Bethesda, MD 20892, USA
    Blood 109:4599-606. 2007
    ..We conclude that alterations of CCND1 3'UTR structure can significantly increase its oncogenic effect and worsen the clinical course of MCL patients...
  57. ncbi Revised response criteria for malignant lymphoma
    Bruce D Cheson
    Division of Hematology Oncology, Georgetown University Hospital, Washington, DC, USA
    J Clin Oncol 25:579-86. 2007
    ..Standardized response criteria are needed to interpret and compare clinical trials and for approval of new therapeutic agents by regulatory agencies...
  58. pmc Aberrant immunoglobulin class switch recombination and switch translocations in activated B cell-like diffuse large B cell lymphoma
    Georg Lenz
    Metabolism Branch, Division of Cancer Treatment and Diagnosis, National Cancer Institute NCI, National Institutes of Health NIH, Bethesda, MD 20892, USA
    J Exp Med 204:633-43. 2007
    ..Accordingly, aberrant switch recombination was responsible for translocations in ABC DLBCLs involving BCL6, MYC, and a novel translocation partner, SPIB...
  59. pmc Loss of major histocompatibility class II expression in non-immune-privileged site diffuse large B-cell lymphoma is highly coordinated and not due to chromosomal deletions
    Lisa M Rimsza
    Department of Pathology, University of Arizona, Tucson, AZ 85724 5043, USA
    Blood 107:1101-7. 2006
    ..Large deletions of the MHCII locus are uncommon in non-IP-DLBCL, implicating altered transcription as the operative mechanism for decreased expression...